UT-XLEAR
Xlear has filed an Amended Answer in response to the U.S. Government’s lawsuit against the company. According to Nathan Jones, Xlear’s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of protection in fighting COVID-19, that our public health officials are ignoring; Second, it lays out in greater detail how the U.S. Government’s lawsuit is an effort to censor science that doesn’t comport with the Government’s vaccine-myopic, failing strategy to combat the disease; Third, it documents how experts, including Dr. Fauci, are increasingly saying the nose is the critical place to fight the virus.
Xlear’s Amended Answer provides two new studies that support the statements Xlear made about the use of its nasal spray as a potential additional layer of protection against COVID-19:
- A new in vitro study found that use of a simple saline solution stops SAR-CoV2 viral replication in human lung tissue. Rafael R. G. Machado, Talita Glaser, Danielle B. Araujo, Lyvia Lintzmaier Petiz, Danielle B. L. Oliveira, Giuliana S. Durigon, Alessandra L. Leal, João Renato R. Pinho, Luis C. S. Ferreira, Henning Ulrich, Edison L. Durigon, and Cristiane Rodrigues Guzzo, ACS Pharmacology & Translational Science 2021 4 (5), 1514-1527, available at https://pubmed.ncbi.nlm.nih.gov/34651104/ . Nate Jones, CEO of Xlear noted, “The Government agrees, Xlear is a saline nasal solution. This in vitro study documents that saline nasal hygiene helps stop COVID-19 from replicating in nasal tissue—which we know is where the virus typically grows and infects people.”
- New in silico research determined that compounds of grapefruit seed extract (GSE) were effective inhibitors of the SARS-CoV-2 virus. Belmina Saric, et al., In silico analysis of selected components of grapefruit seed extract SARS-CoV-2 main protease, EuroBiotech J., 5 (special issue 1); 2021, 5. DOI: https://doi.org/10.2478/ebtj-2021-0015 . Most importantly, these experts concluded natural GSE—which is a component of Xlear—was more effective than synthetic versions of the compound.
Jones continued: “These aren’t the Random Clinical Trials the Government is so focused on—but you can’t deny the mounting wall of evidence that nasal hygiene should be used as an additional layer of protection against COVID-19. Moreover, the Government recently announced that it won’t require Random Clinical Trials for the new variant vaccines—that requirement seems to only apply when it is convenient for the Government.”
Jones also noted that the SARS-CoV-2 variants are all strains of coronavirus, and experts have long recommended nasal hygiene to combat coronaviruses. “As a rule, prevention methods and symptom-reduction modalities (e.g., over the counter drugs, handwashing) are not variant specific; they are used against colds and flus on the whole, many caused by coronaviruses. One countermeasure that experts, including the US Government, recommend to fight the common cold, including coronavirus-infections, is nasal hygiene.” DeGeorge KC, Ring DJ, Dalrymple SN. Treatment of the Common Cold. Am Fam Physician. 2019 Sep 1;100(5):281-289. PMID: 31478634, reprinted by NIH as authority at https://pubmed.ncbi.nlm.nih.gov/31478634/ (“Treatments with proven effectiveness for cold symptoms [coronavirus infections] in adults include over-the-counter analgesics, zinc, nasal decongestants . . . The only established safe and effective treatments for children are . . . nasal saline irrigation . . .”). “It’s commonsense, something our Government’s response to COVID seems to be lacking,” Jones added.
As part of its efforts to silence Xlear, the Government asked the Utah Federal Court to preclude Xlear from filing the Amended Answer. The Federal Court ruled in Xlear’s favor. The Court’s ruling specifically noted: “The court shares some concern here, as expressed by Defendants, that the underlying purpose [in the Government’s motion to prevent Xlear’s Amended Answer] is to prevent discovery into disputed facts that may lend support to Defendants’ proposed amendments.” “In other words, the Government is doing everything they can stonewall us from shining a light on their failed COVID-19 response,” Jones added.
“A new more infectious and more dangerous variant is sweeping the nation. Infections are up. Hospitalizations are up. Deaths are up. At the same time, fewer and fewer people are willing to get vaccinated for the third, fourth, who knows how many times,” Jones noted. “It’s obvious we need a new, broader—'vaccine-plus’—approach. But rather than educate people, the Government is suing us in retaliation for talking about the science. I’m deeply afraid even telling the Court about these new studies will bring more Government retaliation, however in the face of the Government’s failure what choice is there. When science gives way to dogma, people suffer,” Jones concluded.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220815005519/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abu Dhabi Unveils World’s First AI Public Servant at GITEX Global 202514.10.2025 00:23:00 CEST | Press release
Abu Dhabi is unveiling the world’s first AutoGov function with the latest version of TAMM today at GITEX Global 2025. AutoGov automatically manages recurring tasks — from license renewals and utility payments to scheduling routine healthcare appointments — running in the background of daily life so that people have more time to do the things they love and never have to worry about routine services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013919760/en/ His Excellency Ahmed Tamim Hisham Al Kuttab, Chairman of the Department of Government Enablement – Abu Dhabi (DGE) (Photo: AETOSWire) The TAMM AutoGov function launch takes service delivery to the next level, marking a pivotal milestone in Abu Dhabi’s journey to becoming the world’s first AI-native government, representing the next generation of integrated intelligent service delivery. It can automatically manage recurring services, with users having the ability to se
Cessna Citation CJ3 Gen2 achieves FAA type certification, bringing the most comprehensive Gen2 enhancements to market14.10.2025 00:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced the Cessna Citation CJ3 Gen2 has achieved Federal Aviation Administration (FAA) type certification, bringing the most comprehensive Citation Gen2 investment to market. Based on customer feedback, enhancements throughout the aircraft include Garmin autothrottle technology, an additional 4.5 inches of legroom for pilots and a fully customizable cabin environment. After completing 445 flight test hours, the light jet is expected to enter into service this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013311527/en/ Cessna Citation CJ3 Gen2 achieves FAA type certification, bringing the most comprehensive Gen2 enhancements to market (Photo Credit: Textron Aviation). “FAA certification of the CJ3 Gen2 is an example of Textron Aviation’s leadership in certifying aircraft,” said Chris Hearne, senior vice president, Engineering & Programs. “This aircraft de
Cessna Citation M2 Gen2 with Garmin Autothrottles Achieves FAA Certification, Bringing Greater Control and Precision to Pilots14.10.2025 00:00:00 CEST | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently received certification from the Federal Aviation Administration (FAA), bringing greater control and precision to pilots. The integration of Garmin’s Autothrottle system in the M2 Gen2 further supports the most delivered light-entry jet’s capabilities by optimizing engine power, simplifying flight management and increasing overall operating efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013861341/en/ Cessna Citation M2 Gen2 with Garmin Autothrottles achieves FAA certification, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and produced by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. The flight test program for the Citation M2 Gen2 with autothrottles completed nearly 300 flight test hours and numerous certification tests, adhering to stringent certification stan
HCLTech Delivers Robust Performance in Q2FY26 with Revenue Growth of 4.6%13.10.2025 20:08:00 CEST | Press release
Deal wins at $2.6B; Advanced AI revenue crosses $100m HCLTech, a leading global technology company, reported 4.6% YOY revenue growth in constant currency (CC) for the quarter ended September 30, 2025. USD revenue was at $3.6 billion, up 5.8% YoY. The company revised its Services Revenue growth (CC) guidance to 4%-5%, while retaining the overall revenue and margin guidance for FY26. “We had a standout quarter on every front — marked by strong execution, growing demand for our AI-powered solutions and Advanced AI revenue exceeding $100 million this quarter. Our AI strategy is no longer just a vision; it is now a measurable driver of growth, differentiation and innovation. We are transitioning into an AI monetization phase. For the first time, our new bookings surpassed $2.5 billion, without reliance on any mega deal,” said C Vijayakumar, CEO & Managing Director, HCLTech. HCLTech’s Services revenue grew by 5.5% YoY (CC). Digital revenue was up 15% YoY (CC) and now accounts for 42% of Serv
Cessna Citation Ascend Makes World Debut at NBAA-BACE in Las Vegas13.10.2025 19:00:00 CEST | Press release
The Cessna Citation Ascend landed today at Henderson Executive Airport in Las Vegas, marking its world debut at the 2025 National Business Aviation Association Business Aviation Convention & Exhibition (NBAA-BACE). The aircraft, which flew to the show using sustainable aviation fuel, will be on display Tuesday, October 14 and Wednesday, 15 alongside other industry-leading Cessna Citation business jets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013102318/en/ Cessna Citation Ascend makes world debut at NBAA-BACE in Las Vegas (Photo Credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “We asked our customers what they wanted in this iconic aircraft, and our teams worked to bring their vision for the Citation Ascend to life,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “With the aircraft making its debut at NBAA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom